Celebrating Summer Interns: Student Nurses Launched on Their Medical Journey

Updated on Sep 16, 2022 | Community, Diversity and Inclusion, Featured, Nursing

From left: Maria Vezina, EdD, RN, NEA-BC, FAAN, Vice President and Chief of Nursing Practice and Education, nurse intern Daeja Clarke, and Kathleen Parisien Dory, MA, RN, Director of Nursing Education and Professional Development at Mount Sinai Morningside. Each intern received a certificate and heartfelt congratulations.

Nursing Education and Professional Development at Mount Sinai recently honored 63 young people who completed the first system-wide summer program for student nurse interns. The students gained hands-on experience in a hospital setting alongside mentors in a program following the Magnet model of nursing excellence.

“We are so proud of all that our students have accomplished, wish them the best in their professional journey, and look forward to their return here as clinical nurses,” said Maria Vezina, EdD, RN, NEA-BC, FAAN, Vice President and Chief of Nursing Practice and Education, Mount Sinai Health System, who hosted the ceremony at Davis Auditorium on Wednesday, August 10.

The 11-week summer program included nurses who had completed their third year at 23 universities from New York to Nebraska and Oklahoma. Clinical nurse mentors in Mount Sinai Heart, Women and Children’s, Rehabilitation and Human Performance, Critical Care, Surgery, and Medicine guided and supported the students’ learning experiences in units on six campuses. The students have since returned for their last year of college, and the intention is to welcome many back to Mount Sinai after graduation.

Annette Jasko, who was a student nurse intern on 7 West in the cardiothoracic post-surgical unit at The Mount Sinai Hospital, summed up her experience: “Mount Sinai has provided me with an invaluable experience as a student nurse intern that has allowed me to build my skill set, improve my critical thinking abilities, and establish my personal values as a nurse,” she said. “Most important, Mount Sinai has modeled the importance of teamwork and honest values in a way that no other hospital has shown me.”

The ceremony included an inspirational poem on student nurses written by Charlotte Isler, an alumna of the former Mount Sinai Hospital School of Nursing, and heartfelt reflections by mentors, who welcomed students to the profession and encouraged them to remain lifelong learners.

“I hope through your experience with us this summer that you have gained clinical confidence and competence to give you a head start in your nursing career,” Beth Oliver, DNP, RN, Chief Nurse Executive, and Senior Vice President, Cardiac Services, Mount Sinai Health System, said in a message of congratulations. “And I hope you will continue your journey with us at the Mount Sinai Health System.”

A ceremony on Wednesday, August 10, honored the summer interns in nursing.

 

Celebrating Mount Sinai’s 2022 Administrative Fellowship Graduates

Updated on Sep 2, 2022 | Diversity and Inclusion, Featured

Four accomplished young professionals recently graduated from the Mount Sinai Health System’s Administrative Fellowship Program.

The innovative two-year program is managed by the Office for Diversity and Inclusion in collaboration with Human Resources, and strongly supported by system leaders.  It is designed to provide administrative and managerial developmental opportunities to advance underrepresented minority graduates of master’s degree programs into leadership roles within the Health System.

Pamela Abner, MPA, CPXP, Vice President and Chief Diversity Operations Officer, congratulated the fellows during a podcast at the Aspen Ideas Festival on June 27.

“I want to say congratulations to all the Fellows on the great work you have done with Mount Sinai,” Ms. Abner said. “I am amazed by your contributions to Mount Sinai Health System and amazed by what you have accomplished to position yourselves as the next generation of health care leaders.”

The four Fellows who recently completed their two-year rotations within the Health System are Precious Nwajei, MPH; Hazel Rogers; MPH; Oladapo Durojaiye, MS/HSA, MPH; and  Francisca Ruth, MHA.

The Fellows served rotations at Mount Sinai hospitals in fields such as medical education, financial planning and resource allocation, real estate management, data analytics, and patient and staff experience. Fulfilling the mission and promise of the program, the Fellows have all moved into full-time managerial roles within the Health System.

In July 2022, five new Fellows started the program: Hina Akmal MHA; Cordell Downes, MHSA; Aria Kumar, MHA; Estefania Lanza Rodreguez, MPH; and Ashley Sealy, MHA.

The Mount Sinai Health System is accepting applications for the 2023 Administrative Fellowship Program through Friday, October 7. All eligible people, including Mount Sinai employees and students, are encouraged to apply. Contact the Office for Diversity and Inclusion at diversity@mountsinai.org for more information.

Mount Sinai Administrative Fellows Share Takeaway Lessons

The Fellows served rotations at Mount Sinai hospitals in a wide range of administrative fields. They expressed their gratitude to their mentors and discussed some lessons learned.

Precious Nwajei, MPH, Senior Administrative Manager at Mount Sinai Downtown

“One of my major lessons learned is to always be open minded and flexible, because that really opens the opportunity for so many different things. Knowing what you enjoy is important, but also being open to learning about new areas and roles–you might be surprised by what you learn about yourself in process.”

Hazel Rogers, MPH, Assistant Director of Patient Experience and Cultural Transformation at Mount Sinai Morningside

“Remember that your journey is unique, and there is no room for you to compare yourself to others. We will face many trials throughout our lives, but whenever obstacles occur, we must remind ourselves that our faith produces perseverance. To grow as individuals, we cannot run away from challenges. Instead, we must welcome these trials and persevere so that we will become mature and complete throughout our personal growth journey.”

Oladapo Durojaiye, MS/HSA, MPH, Associate Director of Administration at Mount Sinai West

“Hold the vision, be open to learning, remember your WHY, and trust the process. Throughout your fellowship experience, ask questions and never be afraid of making mistakes. Every leader in this organization is genuinely interested in your growth and development. Build relationships and leverage your resources to set yourself apart.”

Francisca Ruth, MHA, Senior Manager, Ambulatory Care Operations at The Mount Sinai Hospital

“Agility is key. Being able to adapt to new situations, team members, workflows will be what makes you stand out. It is important to remember that not everything you do will go exactly as planned, so come in with an open mind and a backup plan. Be ready to step up when needed. This will save you a lot of stress and will be appreciated by all. Change fosters growth.”

Read more about Diversity and Inclusion at Mount Sinai

In Milestone Finding, ‘Polypill’ Reduces Cardiovascular Mortality by 33 Percent in Patients Treated After a Heart Attack

Updated on Aug 26, 2022 | Featured, Research

Valentin Fuster, MD, PhD, at the European Society of Cardiology Congress in Barcelona, Spain

In a milestone in cardiovascular medicine, a  three-drug medication known as a “polypill” was found effective in preventing adverse events such as heart attacks or stroke in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population. These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital.

The study results were announced on Friday, August 26, at the European Society of Cardiology Congress (ESC 2022) in Barcelona, Spain, and published in The New England Journal of Medicine.

“The results of the SECURE study show that for the first time that the polypill, which contains aspirin, ramipril, and atorvastatin, achieves clinically relevant reductions in the recurrent cardiovascular events among people who have recovered from a previous heart attack because of better adherence to this simplified approach with a simple polypill, rather than taking them separately as conventional,” says Dr. Fuster, General Director of the Spanish National Center for Cardiovascular Research (CNIC), which developed the polypill.

Patients recovering from a heart attack—also known as myocardial infarction—are prescribed specific treatments to prevent subsequent cardiovascular events. Standard therapy includes three different drugs: an antiplatelet agent (like aspirin); ramipril or a similar drug to control blood pressure; and a lipid-reducing drug, such as a statin. However, fewer than 50 percent of patients consistently adhere to their medication regimen.

“Although most patients initially adhere to treatment after an acute event such as an infarction, adherence drops off after the first few months. Our goal was to have an impact right from the start, and most of the patients in the study began taking a simple polypill in the first week after having a heart attack,” Dr. Fuster explains.

“Adherence to treatment after an acute myocardial infarction is essential for effective secondary prevention,” says José María Castellano, MD, study first author and Scientific Director of Fundación de Investigación HM Hospitales.

The concept of a polypill for cardiovascular disease prevention was proposed in 2003 and widely debated among experts, with some arguing that it could reduce heart disease at a population level and others arguing that patients could wrongly consider it as a substitute for healthy lifestyles. In 2007, the potential value of applying the polypill strategy in high-risk patients was recognized by the WHO and the World Heart Federation, and Dr. Fuster authored a call to action in Nature Clinical Practice Cardiovascular Medicine,  “A polypill for secondary prevention: time to move from intellectual debate to action.”

Scientists at the CNIC, in partnership with FERRER laboratories, developed a polypill and have conducted a range of studies over the intervening years. CNIC scientists first demonstrated that prescription of the CNIC polypill significantly improved treatment adherence among patients recovering after a myocardial infarction, in the FOCUS study, published in the Journal of the American College of Cardiology (JACC).

The CNIC team launched the SECURE study, an international randomized clinical trial, to determine whether the improved treatment adherence with the polypill translated into a reduction in cardiovascular events. The polypill analyzed in the study, commercialized under the name Trinomia, contains aspirin (100 mg), the angiotensin-converting enzyme inhibitor ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg).

SECURE included 2,499 patients from seven European countries (Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary) recovering after a heart attack. Study participants were randomly assigned to receive standard therapy or the CNIC polypill. The average age of the participants was 76 years, and 31 percent were women. The study population included 77.9 percent with hypertension, 57.4 percent with diabetes, and 51.3 percent with a history of smoking tobacco.

Researchers analyzed the incidence of four major cardiovascular events: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and need for emergency coronary revascularization (the restoration of blood flow through a blocked coronary artery). The study followed patients for an average of three years and produced conclusive results: patients taking the CNIC polypills had a 24 percent lower risk of these four events than patients taking the three separate drugs.

The standout finding of the study is the effect of the polypill on the key outcome of cardiovascular-related death, which showed a relative reduction of 33 percent, from 71 patients in the group receiving standard treatment to just 48 in the polypill group. Importantly, the study found that patients in the polypill group had a higher level of treatment adherence than those in the control group, thus confirming the findings of the earlier FOCUS study, and in part such good adherence appears to explain the benefits of the simple polypill.

“The SECURE study findings suggest that the polypill could become an integral element of strategies to prevent recurrent cardiovascular events in patients who have had a heart attack,” Dr. Fuster says. “By simplifying treatment and improving adherence, this approach has the potential to reduce the risk of recurrent cardiovascular disease and death on a global scale.”

Read the study in The New England Journal of Medicine

Jennifer Chan, PhD, Receives Robin Chemers Neustein Postdoctoral Fellowship Award for Innovative Research

Updated on Aug 31, 2022 | Featured, Research, School

Jenneifer Chan, PhD, and Ian Maze, PhD

Jennifer Chan, PhD, whose work is vastly expanding knowledge about pregnancy, brain health, and stress, is the recipient of the 2022 Robin Chemers Neustein Postdoctoral Fellowship Award, established in 2010 to encourage and support female research scientists at the Icahn School of Medicine at Mount Sinai.

Recipients are senior postdoctoral scientists who intend to complete their training within two years, have demonstrated high-impact accomplishments in biomedical sciences, and exhibit the potential for an independent scientific career. Dr. Chan is the 23rd recipient of the award, created through a generous gift from Robin Chemers Neustein, JD, MBA, a former member of Mount Sinai’s Boards of Trustees.

Dr. Chan works in the laboratory of neurobiologist Ian S. Maze, PhD, in the Nash Family Department of Neuroscience. Dr. Maze, who was appointed as a Howard Hughes Medical Institute (HHMI) Investigator in 2021, is a Professor of Neuroscience, and Pharmacological Sciences, and the founding director of the Center for Neural Epigenome Engineering at Icahn Mount Sinai, the nation’s first center devoted exclusively to neuroepigenomic engineering.

Dr. Maze’s lab is focused on delineating the molecular and biochemical mechanisms of neuroepigenetic plasticity—changes in the underlying biochemical mechanisms that control whether genes are turned on or off within a given cell-type in the brain. This plasticity is important for allowing brain cells to appropriately respond to changing environments, which is critical for proper neurodevelopment—and which can cause disease when there is inappropriate tuning of gene expression.

Jennifer Chan, PhD

For example, aberrations in these processes can produce devastating neurological and psychiatric disorders, such as epilepsy, Parkinson’s disease, Alzheimer’s disease, substance use disorders, and major depressive disorders. These aberrations can occur during brain development or throughout life due to such factors as environmental toxins, physical trauma, chronic stress, and exposure to drugs of abuse.

The Maze lab—through the integration of technologically innovative and sophisticated new methodologies in chemical biology, proteomics, protein biochemistry/engineering, and structural biology—is advancing the understanding of these processes and working toward the development of targeted neurotherapeutics to treat these conditions.

“Using the most advanced epigenomic, metabolomic, and gene editing approaches in my lab, Dr. Chan is revolutionizing our understanding as to how environmental stimuli, both adaptive and maladaptive, impact epigenetic regulation of gene expression in the maternal brain to alter neural circuitry and behavior,” says Dr. Maze. “Delineating the mechanisms through which the experience of pregnancy imparts long-lasting changes in molecular and physiological properties of the brain promises to greatly aid in our understanding of how such a profound lifetime experience—shared by so many—contributes to brain health. Dr. Chan is an exceptionally talented and innovative young scientist, and I am absolutely thrilled by such prestigious recognition of her paradigm-shifting work.”

Dr. Chan joined the lab in 2018. Her research interests focus on understanding how biological systems outside the nervous system interact with stress to impact the brain during windows of neuroplasticity—times of active brain organization that are particularly susceptible to environmental and physiological challenges. Specifically, her work examines periods of early brain development and female reproductive experiences in rodents, including the long-term impact of pregnancy and postpartum experiences on the brain, and how stress disrupts normal organizational processes during these important windows.

“The experience of being pregnant dramatically changes both the body and brain,” says Dr. Chan. “While studies in patient populations and animal models have shown that these changes can persist long after giving birth, we still don’t understand the molecular mechanisms that control these processes.”

In particular, Dr. Chan investigates the contribution of epigenetic mechanisms underlying these experiences by combining molecular, biochemical, genome editing, and behavioral approaches in her postdoctoral research.

“The fundamental understanding of what reproductive experience does to the brain long-term has not been well studied,” says Dr. Chan. “My work shows that stress during these periods has a significant effect on the maternal rodent brain. I hope that through my research we can learn more about how pregnancy and postpartum experiences contribute to brain health and also emphasize that overall we need to do a better job of reducing stress during these critical windows—such as encouraging parental leave and making sure people have the financial, social, and health-related resources needed to support themselves.”

Says Dr. Chan: “I am incredibly honored to be the recipient of this year’s Robin Chemers Neustein Postdoctoral Fellowship Award. The direction for this research project was sparked by personal interest, and I am extremely encouraged by Dr. Maze’s support and that the selection committee also believes in these important questions.”

Read more stories about research at Mount Sinai
Learn more about the Maze Lab

Curious About the Mpox Vaccine? Here’s What You Need to Know

Updated on Dec 6, 2022 | Featured, Infectious Diseases


As cases of mpox, the disease caused by the monkeypox virus, climb in New York City, health professionals and the city Department of Health and Mental Hygiene (DOHMH) have urged people at high risk of contracting the virus to receive the vaccine. DOHMH is making appointments for the vaccine available as quickly as possible, but the vaccine remains in extremely short supply nationwide. Richard Silvera, MD, MPH, Assistant Professor of Medicine (Infectious Diseases), at the Icahn School of Medicine at Mount Sinai, explains what the vaccine is and who should consider getting a shot.

Has a vaccine been approved by the FDA for mpox, and if so, when?

There are two vaccines approved by the U.S. Food and Drug Administration for mpox and smallpox, which are in the same Orthopoxvirus family. JYNNEOS, initially approved in 2019, is currently being used for mpox vaccination efforts. The other is ACAM2000, which was approved in 2007.

How do the vaccines work?

The JYNNEOS vaccine is approved to be administered as two shots subcutaneously, or into tissue under the skin, delivered at least four weeks apart. On August 9, the FDA granted emergency use authorization for the vaccine to be delivered intradermally, or between layers of the skin, to increase availability of doses up to fivefold. DOHMH adopted this guidance on August 23.

ACAM2000, which is not being used for the current outbreak, is administered as a single dose via multiple punctures into the skin using a bifurcated needle.

Both vaccines contain live vaccinia virus, which is also an Orthopoxvirus like mpox. The JYNNEOS vaccine contains attenuated virus. “What that means is there is a virus in the vaccine that has been medically altered to prevent it from reproducing,” Dr. Silvera said. Vaccinated individuals are unable to pass on vaccinia infections to other people around them, unlike with replication-competent vaccines such as ACAM2000.

The vaccine elicits two types of immunities: humoral and cellular, said Dr. Silvera. Humoral immunity involves the building of antibodies that fight off viruses if the body is exposed to them. Cellular immunity involves teaching cells to recognize cells that are infected with viruses and to eradicate those cells. Vaccinia virus has been used as a vaccine for nearly two centuries to fight off more lethal infections, such as smallpox, which was considered eradicated in the United States in the late 1970s.

Is intradermal administration of the vaccine as effective and safe as subcutaneous?

The guidance for intradermal administration of the JYNNEOS vaccine is only for those ages 18 and older. Individuals who are younger would still require the subcutaneous route.

The authorization was granted based on data of a 2015 clinical study that evaluated a two-dose intradermal regimen compared to a subcutaneous one, with the former administered at one-fifth the volume of the latter route of administration.

Results demonstrated that intradermal administration produced a similar immune response to subcutaneous administration. Administration by the intradermal route resulted in more redness, firmness, itchiness, and swelling at the injection site, but less pain, and that these side effects were manageable.

As per the Centers for Disease Control and Prevention (CDC), the city Health Department has adopted the guidance of using subcutaneous delivery to individuals with a history of developing keloid scars. These are raised scar tissue that might occur after a cut or a skin injury.

Am I protected with the first shot? How effective is the vaccine?

“The vaccine does offer some protection after the first shot, but it takes about two weeks after the vaccine is given before that protection comes into play,” said Dr. Silvera. When the two-shot series is complete, it confers about an 80-85 percent effectiveness against infection at the individual level, but its effectiveness at a community level is currently unknown, he added.

Given limited supplies of the JYNNEOS vaccine, the DOHMH is delaying second doses so that more people can get first doses and have some protection. In DOHMH guidance, it added that it is OK to wait longer than four weeks to receive the second dose. Those who received the first dose will be contacted by the Health Department when second doses are available.

Who is considered high-risk and should consider getting the vaccine?

The city is prioritizing appointments for high-risk groups, which currently include men who have sex with men and transgender or gender non-conforming/non-binary people, if they have had multiple or anonymous sex partners in the last 14 days, and transactional sex workers of any sexual orientation or gender identity.

That guidance may change as the epidemic evolves, Dr. Silvera said, adding that health officials are watching the situation closely.

Mpox, however, should not be stigmatized as a sexually transmitted infection unique to the LGBTQ community, Dr. Silvera pointed out. Infections are spread via intimate skin-to-skin contact and sex happens to be one such activity. “No particular person is at high risk of contracting an infection because of who they are,” he stressed.

Video Player

Who should not get the vaccine?

People who have an allergy to the ingredients of the JYNNEOS vaccine should not receive it. The ingredients include gentamicin, ciprofloxacin, and egg protein.

Otherwise, people who meet the eligibility criteria should highly consider the vaccine, Dr. Silvera said.

If I had received a routine smallpox vaccine, am I still protected against mpox today?

Up until 1972, the United States had routine smallpox vaccination, which led to the disease being eradicated. However, people who received a smallpox vaccine then would not be considered to have adequate protection against the current mpox outbreak, Dr. Silvera said, adding that if those individuals meet the criteria for getting the JYNNEOS vaccine, they should seek it.

The CDC guidance, however, stipulates that people who previously have been vaccinated against smallpox can receive just one dose of the JYNNEOS vaccine for adequate protection.

Can I receive a mpox vaccine around the same time as a COVID-19 shot or booster?

The current recommendation is to space out four weeks between receiving a JYNNEOS vaccine and a COVID-19 shot or booster that uses mRNA technology, such as those from Pfizer or Moderna. “That’s to help prevent people from any adverse side effect,” Dr. Silvera said.

However, if vaccination is recommended due to a known exposure to mpox, the individual is encouraged to get the JYNNEOS vaccine even if the person recently received a Pfizer or Moderna vaccine, according to city Health Department guidance.

The story has been updated to include that DOHMH has adopted the guidance regarding administering the mpox vaccine intradermally.

Read more about infectious diseases

White Coat Ceremony at the Phillips School of Nursing Welcomes a New Generation of Nurses

Updated on Aug 5, 2022 | Community, Featured, School

The Phillips School of Nursing at Mount Sinai Beth Israel recently held its annual White Coat Ceremony for nursing students. Held on Monday, July 11, at the Hatch Auditorium at The Mount Sinai Hospital, the ceremony’s speakers included nursing administrators from throughout Mount Sinai Health System who shared their wisdom with the next generation.

“As you leave the stage today, you are now a part of an extraordinary interdisciplinary team, who provide and lead care to our patients,” Beth Oliver, DNP, MSN, Senior Vice President and Chief Nursing Executive at Mount Sinai Health System, said in an address.

Ms. Oliver added that she hoped the 128 students from the December Class of 2022, who donned traditional white coats for the ceremony, would continue their journey at Mount Sinai Health System after they graduated. “I look forward to following your progress as the next generation of nurse leaders and innovators,” she said.

Zeauriya Tabassum, left, and Mirza Tamanna

Originally established by the Arnold P. Gold Foundation in 1993 to welcome students into the medical profession and set expectations for their roles as future physicians, the White Coat Ceremony expanded to all future health care workers, including future nurses, in 2014. For all health care workers, the ceremony symbolizes a commitment to compassionate, humanistic, patient-centered care rooted in scientific proficiency.

The keynote address was given by Maria Vezina, EdD, RN, NEA-BC, FAAN, Vice President and Chief of Nursing Practice, Education, Advanced Practice Nursing Credentialing, and Nursing Labor Relations Partnerships for Mount Sinai Health System. She quoted the late Virginia Henderson, a nurse theorist and educator known as the “first lady of nursing,” who said nurses are “temporarily the consciousness of the unconscious” and “a voice for those too weak to speak.”

From left: Tam Ha, RaeAnne Haggard, and Valmira Helshani

The ceremony concluded with a standing ovation for Lorraine McGrath, MA, RN-BC, Senior Director of Clinical Affairs and Associate Professor of the Phillips School of Nursing, who was recognized for 40 years of exceptional teaching and strong commitment to excellence at the school. Ms. McGrath called the name of each student, while they were cloaked and received their pins from faculty. The pin with a gold Mobius loop from the Gold Foundation, symbolizes the continuous bond of trust, respect, and communication that connects nurses with their patients. Todd F. Ambrosia, DNP, MSN, MBA, APRN, FNP-BC, FNAP, Dean of the Phillips School of Nursing and Vice President of Nursing Affairs at Mount Sinai Health System, closed the ceremony by advising students to “remember always to care for yourselves and for each other.”

Learn more about the Phillips School of Nursing

Pin It on Pinterest